NCT01134822已完成不适用
Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 330
- 试验地点
- 1
- 主要终点
- Discover biomarkers in IPF
研究概览
简要总结
The overall aim of this study is to develop a test that predicts the prognosis of IPF (Idiopathic Pulmonary Fibrosis) and which could be used to determine whether new treatments for IPF are likely to work.
详细描述
The overall objectives of this study are
- Discover and validate novel biomarkers and gene expression profiles for use in subsequent intervention studies in patients with IPF
- To prospectively validate a panel of previously published biomarkers in patients with well characterized idiopathic fibrosing lung disease
- Investigate genetic associations and epigenetic modifications which affect disease severity and progression
- Prospectively evaluate longitudinal disease behaviour in patients with IPF and NSIP with a view to developing composite clinical end-points for subsequent use in intervention studies in patients with IPF
Biomarkers that can be used for the following purposes will be identified:
- Identify patients (Diagnostic)(e.g. discriminate between health and disease)
- Correlate with disease severity (extent of disease, staging of disease)
- Predict clinical progression (Prognostic)(stable vs progressive disease)
- Track response to therapy (Therapeutic response)- Predict response to known efficacious treatments & Correlates with changes in clinical endpoints/mortality/quality of life
- Predict risk of exacerbations (could be used to prevent exacerbations or reduce their severity)
- Correlate with complications and/or comorbidities (e.g. biomarkers of Pulmonary Arterial Hypertension, Gastro Oesophageal Reflux in IPF, etc)
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A diagnosis of IPF using the consensus criteria (32)and Non Specific Interstitial Pneumonia.
- •Between the age group 18-85 years.
- •Sub classified into Mild (TLCO>60), Moderate (TLCO 40-60), Severe (TLCO<40).
- •People who volunteer to undergo a bronchoscopy for research
排除标准
- •People who do not have IPF/NSIP (i.e. Hypersensitivity Pneumonitis, Sarcoidosis)
- •People who cannot give informed consent.
- •People who are being considered for bronchoscopy, any contra-indication to undergoing this procedure as set out in the British Thoracic Society guidelines (Thorax 2001; 56: suppl I: i1-i21). These will be part of the study but not undergo the Broncho Alveolar Lavage.
结局指标
主要结局
Discover biomarkers in IPF
时间窗: 36 months
* Discover and validate novel biomarkers for use in subsequent intervention studies in patients with IPF * To prospectively validate a panel of previously published biomarkers in patients with well characterized idiopathic fibrosing lung disease * Investigate genetic associations and epigenetic modifications which affect disease severity and progression
次要结局
- Survival from Pulmonary fibrosis.(10 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary FibrosisIPFNCT02151435University of Michigan43
已完成
不适用
Prospective Observation of Fibrosis in the Lung Clinical Endpoints StudyIdiopathic Non-specific Interstitial PneumonitisIdiopathic Pulmonary FibrosisNCT01110694Royal Brompton & Harefield NHS Foundation Trust230
已完成
不适用
23andMe IPF Research StudyIdiopathic Pulmonary FibrosisNCT0502889423andMe, Inc.690
Unknown
不适用
Comparing Measurements Made in an Incremental Shuttle Walk Test and a Cardiopulmonary Exercise Test in Patients With IPFIdiopathic Pulmonary FibrosisNCT03360032University Hospitals Coventry and Warwickshire NHS Trust43
已完成
1 期
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001Idiopathic Pulmonary FibrosisNCT05657184Regend Therapeutics12